Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks

BMC Infectious Diseases(2024)10.1186/s12879-024-09655-9Source: DataRank Database

Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks is a research paper published in BMC Infectious Diseases (2024). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.56)OA: goldTopics (57)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Jean‐Marc Schwarz,Nele Brusselaers ORCID,Martin Nabwana ORCID,Robert C. Bollinger ORCID,Allan Buzibye ORCID

Live enrichment

PubMed:39075383 PMC:PMC11285129 OpenAlex:https://openalex.org/W4401091878

NIH-Fogarty University of California (UCSF) global health fellowship program

Grant: 2D43TW009343-06

University of California Global Health Institute Program for Fellows and Scholars

National Institutes of Health, UCSF-Gladstone Center for AIDS Research

Grant: P30AI027763

Fogarty International Center of the National Institutes of Health, Infectious Diseases Institute ‘HIV and coinfections’

Grant: D43TW009771

FIC NIH HHS

Grant: D43 TW009343

National Institutes of Health

Grant: 5D43TW009771-10

HIV CO-INFECTIONS IN UGANDA

National Institutes of Health

Grant: 3P30AI027763-12S2

UCSF-GIVI Center for AIDS research

FWCI

0.56

Citation Percentile

0.7%

Citation Trend

2025

goldLicense: cc-by-nc-nd

journalhttps://bmcinfectdis.biomedcentral.com/counter/pdf/10.1186/s12879-024-09655-9

publisherhttps://bmcinfectdis.biomedcentral.com/counter/pdf/10.1186/s12879-024-09655-9

publisherhttps://link.springer.com/content/pdf/10.1186/s12879-024-09655-9.pdf

publisherhttps://link.springer.com/article/10.1186/s12879-024-09655-9/fulltext.html

journalhttps://doi.org/10.1186/s12879-024-09655-9

Fields of Study

HIV-related health complications and treatmentsDiabetes, Cardiovascular Risks, and LipoproteinsHIV/AIDS drug development and treatment03 medical and health sciences0303 health sciences

MeSH Terms

East African PeopleDolutegravirAdultBlood GlucoseFemaleHeterocyclic Compounds, 3-RingHumansMaleMiddle AgedOxazinesPiperazinesPrediabetic StatePyridonesUgandaCohort StudiesHIV InfectionsTreatment OutcomeHIV Integrase Inhibitors

Keywords

MedicineDiabetes mellitusDolutegravirInternal medicineConfidence intervalChristian ministryHuman immunodeficiency virus (HIV)EndocrinologyAntiretroviral therapyViral loadImmunologyBlood GlucoseIntegrase InhibitorsMaleAdultPyridonesHIV InfectionsInfectious and parasitic diseasesRC109-216East African PeopleArticlePiperazinesPrediabetic StateCohort StudiesOxazinesHumansUgandaHIV Integrase InhibitorsResearchMiddle AgedTreatment OutcomeFemaleHuman medicineHeterocyclic Compounds, 3-Ring

Sustainable Development Goals

SDG 0: Good health and well-being